Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial

Journal:
The Lancet Neurology
Published:
DOI:
10.1016/s1474-4422(26)00100-6
Affiliations:
3
Authors:
15
Go to article
Institutions Authors Share
Lundbeck, Denmark
13.000000
13.000000
 0.87
Mayo Clinic, United States of America (USA)
1.000000
 0.07
Sendai Nishitaga National Hospital, Japan
1.000000
 0.07